SEC Form 4 · accession 0001216055-26-000012
THERMO FISHER SCIENTIFIC INC. · TMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc N Casper
Officer — Chairman & CEO · Director
Period of report
Aug 24, 2026
Accepted (ET)
Aug 26, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000097745
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 24, 2026 | M | 275 | $309.63 | A | 124,200 | D | |
| Common StockF2 | Aug 24, 2026 | S | 101 | $625.41 | D | 124,099 | D | |
| Common StockF3 | Aug 24, 2026 | S | 33 | $626.59 | D | 124,066 | D | |
| Common StockF4 | Aug 24, 2026 | S | 79 | $628.01 | D | 123,987 | D | |
| Common StockF5 | Aug 24, 2026 | S | 62 | $628.74 | D | 123,925 | D | |
| Common StockF6 | holding | — | — | — | 5,000 | I | By MNC 2020 Irrevocable Trust | |
| Common StockF6 | holding | — | — | — | 11,300 | I | By Alison Casper 2020 Irrevocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $309.63 | Aug 24, 2026 | M | 275 | D | — | Feb 25, 2027 | Common Stock | 275 | 0 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.25 to $627.21, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.43 to $628.34, inclusive.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.48 to $628.89, inclusive.
- F6The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
- F7The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.